OncLive TV

Vikram C. Gorantla, MD, discusses real-world treatment patterns with T-DXd vs tucatinib-based therapy in HER2-positive breast cancer with brain metastases.

Robert Neff, MD, discusses how the increasing uptake of HPV vaccination could affect the treatment of patients with cervical cancer.

Vikram C. Gorantla, MD, notes real-world treatment patterns and outcomes with second-line T-DXd vs tucatinib-based therapy in HER2-positive breast cancer.

Robert Neff, MD, discusses how molecular HPV genotyping and testing can be integrated into cervical cancer screening algorithms.

Shubham Pant, MD, discusses data from the phase 3 NAPOLI 3 trial supporting NALIRIFOX as a potent frontline regimen for metastatic pancreatic cancer.

Vikram C. Gorantla, MD, discusses an analysis of T-DXd vs tucatinib plus trastuzumab and capecitabine in HER2-positive breast cancer with brain metastases.

Aditya Bardia, MD, MPH, FASCO, discusses the design of the ELEGANT study of elacestrant vs endocrine therapy in high-risk, ER-positive early breast cancer.

Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, overviews the phase 3 HARBOR trial evaluating elenestinib in indolent systemic mastocytosis.

Jad Chahoud, MD, MPH, discusses key kidney cancer abstracts to watch at the 2026 ASCO Genitourinary Cancers Symposium.

John O. Mascarenhas, MD, discusses the ongoing investigation of various targeted therapies in myeloproliferative neoplasms.

Manish A. Shah, MD, discusses the PFS benefit with zanidatamab plus chemotherapy with/without tislelizumab in HER2-positive GEA regardless of PD-L1 status.

Deepti Radia, MBBS, BSc, MRCPI, FRCPath, MSc Med Ed, discusses long-term data from avapritinib in advanced systemic mastocytosis from the PATHFINDER trial.

Nathan Denlinger, DO, discusses real-world data with second-line liso-cel and axi-cel in patients with relapsed/refractory large B-cell lymphoma.

Fernando Gibran-Nunes, MD, highlights findings from a meta-analysis investigating the efficacy and safety of loncastuximab tesirine in pretreated DLBCL.

Peter Riedell, MD, discussed the long-term efficacy of tisagenlecleucel in the third-line setting in patients with relapsed/refractory follicular lymphoma.

Kenneth Jin Chang Lim, MBBS, discusses the failure of dexamethasone to reduce rates of neurotoxicity in myeloma with high ALC after CAR T-cell therapy.

Yue Wei, PhD, discusses using single-cell sequencing and patient data to validate HMA effects on megakaryocyte maturation in MDS.

Robert Neff, MD, highlights the role of oncology-led advocacy in improving screening uptake in cervical cancer.

Sagar Lonial, MD, FACP, FASCO, discusses the potential role of CELMoD-based combination approaches in newly diagnosed, transplant-ineligible multiple myeloma.

Mabel Mardones, MD, discusses how Dato-DXd and sacituzumab govitecan may affect first-line treatment for metastatic triple-negative breast cancer.

Louis Potters, MD, FASTRO, FABS, FACR, discusses the meaning of World Cancer Day and highlights the importance of early detection and screening.

Alexander B. Olawaiye, MD, discusses updated OS data from the phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in PROC.

Ryan D. Chow, MD, discusses real-world data showing that upfront enfortumab vedotin dose reduction can improve tolerability without affecting survival.

David Rimm, MD, PhD, discusses the strategic sequencing of ADCs in breast cancer, asserting that these agents should be classified as targeted therapies.

Joyce O’Shaughnessy, MD, discusses the rationale for the ongoing ELEGANT trial of elacestrant in high-risk, ER-positive, HER2-negative early breast cancer.

Nicholas James Short, MD, discusses the roles of molecular and genetic testing in Philadelphia chromosome–positive acute lymphoblastic leukemia.

Rahul Banerjee, MD, FACP, discusses the potential long-term role of CELMoDs in the multiple myeloma treatment paradigm.

William A. Hall, MD, discusses the rationale of the phase 2/3 Janus Rectal Cancer Trial.

Kanwal P.S. Raghav, MBBS, MD, discusses standards for data interpretation in clinical trials involving ctDNA testing in CRC.

Xiuning Le, MD, PhD, discusses the mechanism of action of sevabertinib in HER2-mutated NSCLC.